JCB, Volume 22, Number 2, 2016 Commentary Vol.22 No. 2 (2016) Of Pens, Pizzas, and Pharmaceuticals Peter J. Pitts Much ado about pharma freebies to physicians. Much ado about nothing medically and everything politically. A new study published by JAMA Internal Medicine (Pharmaceutical Industry� Article Vol.22 No. 2 (2016) Intellectual Property Business Models Using Patent Acquisition: A Case Study of Royalty Pharma Inc. Su Young Lim In the pharmaceutical industry, companies are currently facing great challenges in developing new products due to patent expiration and decreasing profitability. In partic Article Vol.22 No. 2 (2016) Manage Complexity and Uncertainty in Biotechnological Innovations: Converting Theoretical Advances into Opportunities Jonathan Baert Article Vol.22 No. 2 (2016) The Chinese medical device market: Market drivers and investment prospects Weifan Zhang The economy in China has experienced rapid growth and been remarkably successful ever since the reforming and opening-up policy. Like China’s economy, the Chinese medical device ma Article Vol.22 No. 2 (2016) Investor experience in biotechnology William Bains Biotechnology is viewed as an industry that combines scientific innovation, entrepreneurial management and experienced investment to drive innovation, primarily in biomedicine. This paper Article Vol.22 No. 2 (2016) The BIEM Verification Study: Experienced Venture Capitalists Assess a Biopharmaceuticals Innovation Expertise Model Moira A. Gunn Developing biopharmaceutical therapies is a scientifically complex endeavor, requiring from ten to fifteen years of effort with successive rounds of increasingly greater investment capital i Intellectual Property Management Vol.22 No. 2 (2016) Recent Developments in Compulsory Licensing of Pharmaceutical Patents in India Viren Konde On March 9, 2012, under Section 84(1) of the Indian Patents Act, Controller General of Patents granted country’s first and only compulsory licence to Natco Pharma to sell Bayer AG� Legal and Regulatory Updates Vol.22 No. 2 (2016) Post-Grant Review of U.S. Patents: A Primer Stefan Michael Miller The validity of an issued U.S. patent may be challenged in a number of forums including the courts and before the United States Patent & Trademark Office. With the enactment of the Le Conference Report Vol.22 No. 2 (2016) Technology Commercialization & Partnerships for Global Health Vasu Pestonjamasp
